U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT06985576) titled 'Long-term Study to Evaluate Safety and Persistence of GF-CART01' on May 15.
Brief Summary: The goal of this observational study is to learn about the long-term safety of GF-CART01 after cell infusion up to 15 years.
Study Start Date: May, 2026
Study Type: OBSERVATIONAL
Condition:
DLBCL - Diffuse Large B Cell Lymphoma
Follicular Lymphoma (FL)
Primary Mediastinal Large B-Cell Lymphoma
High Grade B Cell Lymphoma
Recruitment Status: NOT_YET_RECRUITING
Sponsor: GenomeFrontier Therapeutics TW Co., Ltd.
Disclaimer: Curated by HT Syndication....